A physiologically based pharmacokinetic (PBPK) model for hexavalent chromium [Cr(VI)] in mice, rats, and humans developed previously (Kirman et al., , 2013 , was updated to reflect an improved understanding of the toxicokinetics of the gastrointestinal tract following oral exposures. Improvements were made to: (1) the reduction model, which describes the pH-dependent reduction of Cr(VI) to Cr(III) in the gastrointestinal tract under both fasted and fed states; (2) drinking water pattern simulations, to better describe dosimetry in rodents under the conditions of the NTP cancer bioassay; and (3) parameterize the model to characterize potentially sensitive human populations. Important species differences, sources of non-linear toxicokinetics, and human variation are identified and discussed within the context of human health risk assessment.
Introduction
As trivalent [Cr(III)] and hexavalent [Cr(VI)] forms, chromium is both naturally occurring and found in anthropogenic sources (McNeill et al., 2012; Oze et al., 2007) . Human exposures to low concentrations of Cr(VI) in drinking water are widespread with average concentrations in the US drinking water supply to range from~0.0002 ppm to 0.001 ppm (EWG, 2011; U.S. EPA, 2014) . Higher concentrations of Cr(VI) can occur in drinking water as a result of past industrial activity. Concerns for potential risk from these exposures arise from observations that Cr(VI) produces tumors of the small intestines in mice and the oral cavity of rats following chronic exposure to high concentrations of Cr(VI) in drinking water (NTP, 2008a) . A physiologically based pharmacokinetic (PBPK) model was developed for Cr(VI) in rodents and humans (Kirman et al., 2013) to support key extrapolations in a human health risk assessment: (1) interspecies extrapolations of equivalent doses; and (2) extrapolation from high concentrations to low concentrations. Of critical importance is the models' ability to characterize the detoxification of Cr(VI) by extracellular reduction to Cr(III) in the gastrointestinal lumen.
A number of data gaps and limitations were identified in our previous work. These include the need for: (1) characterization of Cr(VI) reduction in human fed gastric samples, because all previous work in human gastric samples were from fasted individuals; (2) better characterization of Cr(VI) reduction at elevated pH, because previous work included only a single data point above a pH of 4; and (3) characterization of Cr(VI) reduction in individual samples, because previous work was largely based on gastric content samples pooled across individuals. In addition, recommendations have been made to improve the form of the reduction model, by increasing the number of reducing agent pools and refining the pH-dependence of the reduction reaction (Schlosser and Sasso, 2014; Kirman et al., 2016) . In the work presented below, the PBPK model for Cr(VI) is updated to address many of these data gaps and limitations.
Material and methods
In this study, the PBPK model of Kirman et al. (2012 Kirman et al. ( , 2013 has been updated to include several refinements: (1) a revised reduction model; (2) a more realistic depiction of rodent drinking water exposure patterns; and (3) a simplification of the human model, along with Toxicology and Applied Pharmacology 325 (2017) 9-17 Abbreviations: Cr, chromium; Cr(III), trivalent chromium; Cr(VI), hexavalent chromium; GI, gastrointestinal; PBPK, physiologically based pharmacokinetic.
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Reduction model
Extracellular reduction of Cr(VI) to Cr(III) in gastric contents was quantified across a range of concentrations and pH values. Based upon time-course data collected for the reduction of Cr(VI) by gastric contents from mice, rats, and humans ( Fig. 1A ; Kirman et al., 2016) , a reduction model was developed to describe the extracellular reduction of Cr(VI) to CrIII ( Fig. 1B ; Kirman et al., 2016 ). The reduction model is then incorporated within the gastrointestinal lumen compartments of the PBPK model ( Fig. 1C ; reaction R2a). The previous version of the reduction model described Cr(VI) reduction using a single pool of reducing agents Kirman et al., 2012) . For this work, the reduction model has been revised to include multiple pools, as recommended by Schlosser and Sasso (2014) , based on a larger, more robust set of data (Kirman et al., 2016) . The rate of Cr(VI) reduction is best described as three reduction reactions: (1) a fast, second order reaction; (2) a slow, second order reaction; and (3) a very slow, first order reaction. The net reaction is defined as follows (Kirman et al., 2016) :
where K Red is a rate constant for reduction (expressed in terms of L 2 / mg-hr or h −1 ) for a specific pool of reducing equivalents, C RE is the concentration of reducing equivalents or reduction capacity (mg/L) for a specific pool of reducing agents, C Cr(VI) is the concentration of Cr(VI) (mg/L); and values for K Red and C RE differ between pools (i.e., reduction reactions can occur at different rates, with different capacities). The term reducing equivalent is used here for the sake of simplicity to refer to a pool of three-electron donors needed to reduce hexavalent chromium to trivalent chromium.
In the previous version of the reduction model, the pH dependence was described using a simple, log-linear model (Kirman et al., 2013) , which was based on reduction data from a limited range of pH values. For this work, the pH dependence of the reduction of Cr(VI) in the gastrointestinal lumen was described using a piecewise log-linear model (Kirman et al., 2016) , to account for different behavior at high pH vs. low pH (i.e., above or below an apparent inflection point) informed by the observed reduction data.
where M low = slope at low pH (b P), B low = intercept at low pH, M high = slope at high pH (NP), B high = intercept at high pH, and P = inflection point between low and high pH. Parameter values for the reduction model are provided in Table 1 .
Modeling rodent drinking water exposures
In the previous version of the model, rodent exposures to Cr(VI) were simulated using a simple assumption of continuous infusion (i.e., 24 h/day). For the revised model, rodent exposures to Cr(VI) were modeled as a series of distinct drinking water bouts over the course of the day based on drinking water pattern data collected for mice (Gannon et al., 1992) and rats (Glendinning and Smith, 1994) . Drinking water pattern information for both species during day and night time periods adapted from Gannon et al. (1992) and Glendinning and Smith (1994) are summarized in Table 2 . In addition, whereas the previous version of the PBPK model assumed that the volume of the gastric lumen was a constant value, the revised version of the model permits this volume to vary with drinking water intake and gastric emptying times. Physiological parameter values for mice and rat remain the same as defined previously , and are provided in Appendix A. Model parameters for Cr absorption and systemic tissue delivery were derived by fitting the revised PBPK model (i.e., with updated reduction model and drinking water exposure pattern) using the same approach as described previously . The general approach involved first defining model parameter values for describing Cr(III) toxicokinetics, then holding the Cr(III) parameters and the reduction model parameters fixed, the Cr(VI) model parameters were adjusted to obtain fits to the key data sets identified for Cr(VI). Predictions from the revised model compared to available toxicokinetic data sets for rats (NTP, 2008a (NTP, , 2008b Thomann et al., 1994; Kirman et al., 2012) and mice (NTP, 2008a (NTP, , 2008b Kirman et al., 2012) are provided in Appendix A. Using the revised PBPK model, internal dose estimates for the gastrointestinal tract were determined for mice and rats under the conditions of the NTP cancer bioassay (NTP, 2008a (NTP, , 2008b .
Modeling human exposures
Only a portion of the human PBPK model was needed to support human health risk assessment. Specifically, pyloric flux, whose numerator is defined as the daily amount of Cr(VI) transiting the stomach lumen (i.e., past the pylorus) to the small intestines lumen, and denominator defined as the volume of the small intestines tissue (mg Cr(VI)/kg SI-day), was used to support interspecies extrapolation using the PBPK model, as was done previously (Thompson et al., 2014) . This dose measure only requires defining model parameters for the gastric compartment, volume of small intestines tissue, and body weight. As noted by Thompson et al. (2014) , pyloric flux measure can be estimated with a relatively high degree of confidence since the small number of model parameters needed are based on measured values that are known with a high degree of certainty. Small intestines flux, or mg Cr(VI) taken up by small intestines/kg small intestines per day, is considerably more uncertain, but yielded very similar predictions for human risk (Thompson et al., 2014) . For this reason, future applications of the human PBPK model will be focused exclusively on the use of pyloric flux in human health risk assessment.
Key factors contributing to the delivery of Cr(VI) to the small intestines (SI) were identified by sensitivity analyses for the previous version of the model Kirman et al., 2013) , and are expected to remain the same for the revised PBPK model. Sensitive parameters include gastric pH, Cr(VI) reduction rate constant, gastric transit time, and gastric reducing equivalents. These factors affect the rate of Cr(VI) reduction in gastric contents and delivery of Cr(VI) to the small intestines.
Factors that result in higher doses of Cr(VI) to the intestines include higher gastric pH values (which results in slower rates of Cr(VI) reduction), shorter stomach transit times, and lower reducing equivalent concentrations. The revised human PBPK model was used to address several important sources of variation: (1) diurnal variation and timing of exposure events; (2) variability in toxicokinetic factors for sensitive subpopulations; and (3) variation across age groups.
2.3.1. Diurnal variation and exposure timing. The revised PBPK model was used to account for normal diurnal variation in gastric lumen factors. For example, in normal individuals, baseline gastric pH is typically between 1 and 3 between meals, but rises rapidly to levels of 5-7 at the start of a meal, then returns to baseline levels within approximately 2 to 4 h (Dressman et al., 1990; Russell et al., 1993; Nagita et al., 1996; Omari and Davidson, 2003) . The return of gastric pH from peak values during the meal to baseline exhibits different behavior for different age groups. In older adults and in infants, the return to baseline exhibits a linear behavior (Omari and Davidson, 2003; Dressman et al., 1990; Russell et al., 1993) , while in young adults the return to baseline appears nonlinear. For risk assessment, a linear return to baseline gastric pH was assumed for neonates, infant/child, and elderly scenarios, and a nonlinear return to baseline was assumed for youth and adult scenarios. Dichotomous values for fed and fasted states were adopted for gastric transit rate and reducing equivalent concentration based on information from the published literature (ICRP, 2002; De Flora et al., 1987) and this study, where fed and fasted states are defined in terms of the presence or absence of food in the stomach lumen, respectively. 24-Hour time-profiles were developed for the following model parameters (model code parameter indicated in parentheses): gastric pH (phs), gastric transit rate (klsd), and concentration of reducing equivalents in gastric contents (cre0) ( Table 3) .
Because the delivery of Cr(VI) to the small intestines will be different when exposure occurs during a fed state (i.e., during meals, for the few hours when food is present in the stomach and gastric pH is elevated) vs. during a fasted state (i.e., between meals, when food is absent and gastric pH is at baseline), the PBPK model was used to assess the impact of the timing of Cr(VI) exposure events. For the default assumption, half of the daily exposure events were assumed to occur during a fasted state, and the other half of the daily exposure events were assumed to occur during a fed state. The impact of assuming 100% of exposure events occurring during either state were also assessed. Drinking water exposure scenarios for each age group was based upon the drinking water consumption survey data collected by Barraj et al. (2009) . Specifically, the average number of daily drinking water events for each age group was rounded up to the next even number, with half of the events assumed to occur during a fasted state (at hours 7, 16, and 22), and the other half assumed to occur during a fed state (at hours 8, 12, and 18). The relationship between administered dose of Cr(VI) and pyloric flux was estimated for various exposure conditions across a broad range of administered doses of Cr(VI) (0.0001-10 mg/kg).
Sensitive subpopulations.
The model was used to assess risk to specific sub populations [e.g., proton-pump inhibitor (PPI) users and persons with hypochlorhydria/achlorhydria] that may be sensitive to ⁎ The very slow reaction was modeled as a first order reaction (i.e., unlimited reduction capacity).
Table 2
Drinking water intake patterns for mice and rats.
Mice (Gannon et al., 1992) Rats (Glendinning and Smith, 1994) Cr(VI) due to elevation in gastric pH, which decreases the pH-dependent reduction of Cr(VI) in the GI lumen, which in turn results in greater delivery of Cr(VI) to the small intestines. For PPI user simulations, a 24-hour gastric pH profile was developed based on the data collected by Atanassoff et al. (1995) . Specifically, the arithmetic mean for 4 treatment scenarios (2 medications, omeprazole and ranitidine, each at 2 dose levels) was used. For hypochlorhydria simulations, the gastric pH data of Ayazi et al. (2009) were used. In this study gastric pH in 1582 individuals exhibited a bi-modal distribution. Inspection of these data from this study suggest that a pH of approximately 3.7 serves as a natural cutoff point between these two distributions, with approximately 92% of the samples falling below this point (i.e., reflective of a normal, healthy population) and approximately 8% of the samples falling above this point (i.e., hypochlorhydria). Data for the hypochlorhydria subpopulation were digitized and then used to estimate a central tendency (median pH = 4.2) and upper bound values (90th percentile pH = 6.0). Each of these values was used separately as the baseline gastric pH values for the evaluation of hypochlorhydria.
2.3.3. Variation across age groups. Age-specific differences in the key factors were incorporated in the modeling to estimate human equivalent lifetime average daily dose (LADD). Including of age-specific parameters in the evaluation was considered important because some age groups normally exhibit baseline and/or peak pH values that are higher than an average adult (Dressman et al., 1990; Russell et al., 1993; Nagita et al., 1996; Omari and Davidson, 2003) . For example, baseline gastric pH in neonates is approximately twice the value of that in an adult. However, this elevated baseline gastric pH is relatively short-lived, and demonstrates a significant decrease during the 2nd week post-partum (Sondheimer et al., 1985) , reaching approximately adult gastric pH levels by 3 months of age (Milsap and Jusko, 1994) . Because of the differences in gastric pH, differences in the pH-dependent reduction of Cr(VI) in the GI lumen are expected between age groups. The PBPK model was used to simulate exposures to 5 different age groups, including neonates (0-3 months), infants/children (3 months-6 years), youth (6-18 years), adults (18-60 years), and the elderly (60-75 years). Age-specific values for body weight, tissue and lumen volumes, and transit rates were obtained from published reviews (ICRP, 2002; USEPA, 2011) , and are summarized in Table 3 .
The relationship between administered dose of Cr(VI) and pyloric flux was estimated for each age group across a broad range of administered doses of Cr(VI) (0.0001-10 mg/kg). At each administered dose level, the LADD was calculated as a time-weighted average of the internal dose estimated for each age group:
where, LADD = lifetime average daily dose for pyloric flux (mg/kg SIday), DDi = daily dose for pyloric flux for each age group (mg/kg SIday), and EDi = exposure duration (year).
Sensitivity analyses.
To help identify model parameters that are important to predict dose metrics to be used in risk assessment (e.g., pyloric flux), sensitivity analyses were conducted. Model parameter values were adjusted by a nominal amount (5%) and the sensitivity coefficients were calculated as follows:
where,PFpv1 = predicted pyloric flux value using unadjusted model parameter value. PFPV1.05 = predicted pyloric flux value using model parameter value increased by 5%. In all three species, sensitivity analyses were conducted at high doses, corresponding approximately to the levels associated with point of departure values for toxicity endpoints. In addition, a sensitivity analysis was conducted in humans at low doses, corresponding approximately to the levels associated with the existing MCL for CrVI. The top ten model parameters for each species were identified. 2.3.5. Software. All PBPK modeling was performed in acslX (Aegis TG, version 3.0) along with its interface for Excel (Microsoft). Data from the published literature that was contained within figures were converted to numerical values using GraphClick (Arizona Software, version 3.0).
Results
The revised PBPK model provided good fits to available rodent data sets, and are generally similar to fits reported previously . Example fits of the model to the mouse tissue data collected by NTP are provided in Fig. 2 , and those for all other data sets are provided in Appendix A. Using the revised model, predictions for various internal dose measures in female mice under the conditions of the cancer bioassay conducted by NTP for Cr(VI) are presented in Fig. 3 . Due to rapid clearance processes (transit, reduction, tissue uptake), the model predicts that Cr(VI) does not accumulate in the gastric lumen from one drinking water bout to the next, even at the highest tested dose (Fig.  3A) . Across all tested doses, reducing equivalents for the fast reduction reaction (C RE1 ) are predicted to be significantly depleted shortly after each drinking water bout (decreased to approximately 36%, 15%, 4%, and 0% of unexposed animal predictions for adult female mice exposed to doses of 0.46, 1.8, 4.8, and 12 mg/kg respectively), with recovery (i.e., returning to levels approximately equivalent to unexposed animal levels) predicted prior to the next drinking water bout (Fig. 3B ). Decreases in the reducing equivalents for the slow reduction reaction (C RE2 ) are also predicted, but are less severe (to approximately 50% at the highest dose; data not shown), again with recovery prior to the next drinking water bout. Due to the depletion of reducing equivalents, predicted pyloric flux (expressed on a per administered dose basis) exhibit nonlinear behavior, and are approximately 2.5-fold higher at the highest tested dose when compared to lowest test dose (Fig. 3C ).
Model predictions for these internal doses in rats under the conditions of the NTP cancer bioassay were qualitatively similar to the predictions described above to mice (data not shown). PBPK model predictions for an example human exposure scenario are depicted in Fig. 4 . In this simulation, an average, healthy adult is exposed to 0.1 mg/kg-day Cr(VI) spread over 6 exposure events (3 occurring during meals, 3 occurring between meals) (Fig. 4A) . Gastric lumen concentrations are predicted to be higher for between meal exposure events (i.e., fasted state) than for during meal events (i.e., fed state), largely attributable to a smaller volume of lumen contents during these times (Fig. 4B) . At this dose level, the concentration of reducing equivalents (fast reaction pool, CRE1) in the gastric lumen is predicted to be significantly depleted after each exposure event (Fig. 4C) , and corresponding values for cumulative pyloric flux are provided in Fig. 4D .
Predictions of pyloric flux in humans are affected by a number of factors and sources of variation. The effects of exposure timing with respect to meal consumption (i.e., fed = during meals or fasted = between meals) can be predicted (Fig. 5A ). As noted above for rodents, nonlinear toxicokinetics are predicted to occur due to the depletion of gastric reducing equivalents, which is evident in the curvature noted between doses of 0.01 and 0.1 mg/kg-day. Although toxicokinetic factors during meals that favor higher gastric flux estimates include higher gastric pH (i.e., less Cr(VI) reduction), factors that favor higher gastric flux estimates for exposures between meals include faster transit rates (i.e., less time for Cr(VI) reduction to occur) and lower gastric content volumes (i.e., more readily depleted). Because of these competing factors it is not intuitive as to which Cr(VI) exposures (those occurring during meals or between meals) contribute greater delivery of Cr(VI) to the small intestines. The PBPK model predicts that the impact of feeding status has a relatively small impact on pyloric flux values. At low doses (b0.01 mg/kg-day), the fed state (during meals) produces slightly higher estimates of pyloric flux than the fasted state. However, at high doses (N0.01 mg/kg-day) the opposite is predicted, due to a more pronounced depletion of reducing equivalents associated the fasted state (i.e., small volume of gastric contents).
PBPK model predictions were made to assess the effect of the number of drinking water events by which a given daily dose is divided over the course of a day (Fig. 5B) . As expected, pyloric flux estimates were highest when exposure consisted of a single drinking water event, but the magnitude is dose-dependent, being 3-fold higher than the pyloric flux estimates predicted for the default assumption (6 events) at low doses, but approaching no difference at high doses. Conversely, pyloric flux estimates were lowest when exposure was assumed as continuous infusion (i.e., an infinite number of drinking water events), across all doses was within a factor of 2 of the pyloric flux values predicted for the default exposure assumption, and again approaching no difference at high doses.
PBPK model predictions for potentially sensitive subpopulations are depicted in Fig. 5C . At low doses (b0.01 mg/kg-day), PPI users, and people with hypochlorhydria (evaluated at the mean for gastric pH) are predicted to experience higher gastric flux estimates than the average adult by factors of approximately 2, 3, and 5, respectively. At high doses (N0.1 mg/kg-day), the curves converge such that the differences between these subgroups is less than a factor of 2.
PBPK model predictions of LADD as a function of administered dose are depicted in Fig. 5D , as well as the daily dose predictions for various age groups. At low doses (b 0.01 mg/kg-day), neonates are predicted to experience higher gastric flux estimates than other age groups due to a higher baseline gastric pH value (i.e., less Cr(VI) reduction occurring) and faster gastrointestinal transit rates (i.e., less time for reduction to occur before reaching the small intestines). Conversely, at high doses of Cr(VI) (N 0.1 mg/kg-day), where little Cr(VI) is reduced in any age group (and therefore gastric pH has little impact), neonates are predicted to experience lower gastric flux than other age groups due to a higher relative volume for small intestines tissue (used in the denominator for flux).
The results of the sensitivity analyses for model predictions of pyloric flux of CrVI following oral doses of CrVI are summarized in Table 4 . At high oral doses (0.25 mg/kg-day), rodent parameters for the reduction model (slope and intercepts for pH-dependent reduction rate term, reducing equivalents) and gastrointestinal physiological parameters (gastric pH, transit rates, tissue volume) identified as the most important parameters. Similar results were noted for human at high doses. At low doses, where the reduction capacity of the fast reducing pool of reducing agents has not been depleted, the relative importance of parameters for the fast reducing pool (interlof) is greater than at high doses, where the importance of parameters for the slow reducing pool (interlos) predominates, which confirms that the results of the sensitivity analysis are dose-dependent, consistent with the presence of nonlinear toxicokinetics.
Discussion/conclusions
A previously published PBPK model for Cr(VI) was revised to reflect recently collected information, more realistic assumptions regarding rodent exposures, and better describe human variation and sensitive subpopulations. The revised PBPK model developed here continues to provide a reliable description of Cr(III) and Cr(VI) toxicokinetics in rats and mice based upon available toxicokinetic data (Appendix A). Under the conditions of the NTP cancer bioassay for Cr(VI) in rats and mice, nonlinear toxicokinetics due to depletion of reducing equivalents (fast reaction pool) are predicted to occur in rats and mice under conditions of the NTP bioassay. The dose-dependency of PBPK model predictions, due to depletion of gastric reducing equivalents, is depicted in Fig.  6 for each species. At low doses (b 0.01 mg/kg-day), the percentage of Cr reaching the small intestines as Cr(VI) is greater in mice than in other species, primarily due to the relatively short transit time for gastric contents (i.e., little time for Cr(VI) reduction to occur). As reducing equivalents become depleted (particularly for the fast reaction pool), the percentage of Cr leaving the stomach and reaching the small intestines as Cr(VI) increases with dose. Nonlinear toxicokinetics are predicted by the PBPK model to occur in humans at doses N0.01 mg/kg-day, in mice and rats at doses N 0.1 mg/kg-day, largely due to differences in reduction capacity for the fast reduction reaction. These predictions are in contrast to those that would be obtained using allometric scaling, which using a body weight scaling factor of ¾ would predict humans experience internal doses of Cr(VI) that are approximately 7-fold higher than experienced by mice at a given administered oral dose. Both sources of nonlinear toxicokinetics complicate the interspecies extrapolation step in human health risk assessment (e.g., calculation of human equivalent doses for rodent-based point of departure). In short, the results of an interspecies extrapolation are expected to be dose-dependent, and are best handled within the framework of the PBPK model.
Model predictions for internal doses in mice and humans from the revised PBPK model are compared to those made by the previous version of the model in Fig. 7 . In mice exposed under the conditions of the NTP cancer bioassay (NTP, 2008a (NTP, , 2008b , the revised model predicts SI sectional flux estimates that are slightly higher than the previous version of the PBPK model, whereas predictions for pyloric flux are slightly lower. Overall, the changes in model predictions are relatively modest (up to a factor of approximately 2-fold). In humans, both versions of the model make very similar predictions for pyloric flux at low doses. At higher doses, the revised PBPK model predicts higher values for pyloric flux in humans than did the previous version of the model, which is largely attributed to the relatively low estimates obtained for the concentration of reducing equivalents (fast reduction reaction) in fed human gastric samples (0.68 mg/L; Kirman et al., 2016) . Again, the changes in model predictions are relatively modest (less than a factor of 2-fold). The net impact to human health, which reflects the ratio of the two model predictions, is difficult to predict. Changes in mouse internal dose predictions generally result in decreased potency with respect to SI sectional flux, but increased potency with respect to pyloric flux. Changes in the human internal dose predictions are expected to result in predictions of increased risk at high doses, but effectively no change at low doses. Overall, the impact of the revised PBPK model on quantitative portions of the risk assessment is expected to be fairly small (less than a factor of 2). However, any small quantitative impact is accompanied by a significant increase in confidence (reduced uncertainty) since the revised model incorporates additional data that fill data gaps identified in the previous PBPK model.
Sources of uncertainty for the rodent models generally remain the same as described previously. Although additional information has been included to better simulate exposure patterns in rodents, treatment-related effects on drinking water patterns in rodents appear likely, given that water intakes were reduced in a dose-dependent manner (NTP, 2008a (NTP, , 2008b . It is unclear if the effects of Cr(VI) include reduction in drinking bout frequency, size, or both.
Sources of human variation, including diurnal variation relative to exposure timing, variation across age groups and sensitive subgroups (PPI users, hypochlorhydria), can affect predictions of pyloric flux to varying degrees. The effects of these sources of variation are complex, and in some cases are dose-dependent, having differential effects at high vs. low doses. The net impact of factors such as PPI use and hypochlorhydria on model predictions for the LADD will depend in part upon assumptions made for their relative duration. For PPI use, a mean duration of 18.2 months has been reported for adults (Dharmarajan et al., 2008) , suggesting that this is best characterized as a subchronic duration. In contrast, hypochlorhydria appears to reflect a chronic condition that is associated with H. pylori infection, whose prevalence increases with age (Seo et al., 2015; Nagy et al., 2016) . Individual variation is also expected to be significant. Variation in reducing equivalents, which reflects a combination of individual and temporal factors, was large, with coefficients of variation exceeding 100% for CRE1 and CRE2 values in humans determined for both fasted and fed conditions (Kirman et al., 2016) . Because of these complexities, sources of human variation and the impact on human health risks are best addressed within the framework of the PBPK model.
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